Key Takeaways
- President Trump issued an executive directive Saturday instructing the FDA to expedite psychedelic drug evaluations for mental health treatment
- Shares of AtaiBeckley surged 28% in premarket activity; Compass Pathways climbed 26%
- The directive introduces Commissioner’s National Priority Vouchers for breakthrough-designated psychedelic therapies, reducing evaluation periods from 6–10 months to just 1–2 months
- The order specifically mentions ibogaine, a Schedule I compound under investigation for treating opioid dependency
- Federal authorities will dedicate $50 million toward ibogaine research initiatives
On Saturday, President Trump issued an executive directive instructing the Food and Drug Administration to expedite the evaluation process for psychedelic medications. The executive action carries the title “Accelerating Medical Treatments for Serious Mental Illness.”
[[SCRIPT_0]]The presidential order encompasses therapeutic interventions for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders.
FDA Commissioner Marty Makary indicated that regulatory determinations on certain medications could be announced as early as this summer.
The directive dramatically reduces standard evaluation timeframes from 6–10 months to merely 1–2 months for medications already granted “breakthrough therapy” status. This acceleration is achieved through the implementation of Commissioner’s National Priority Vouchers.
Publicly traded psychedelic pharmaceutical companies experienced substantial gains in Monday’s premarket session. AtaiBeckley surged 28%, Compass Pathways advanced 26%, GH Research gained 19%, Definium Therapeutics increased 15%, Cybin rose approximately 15%, and Enveric BioSciences added 7%.
With a market capitalization approaching $1.5 billion, AtaiBeckley stands as one of the largest publicly listed entities in the psychedelic pharmaceutical sector.
Market Response to Presidential Initiative on Psychedelic Therapies
The company’s primary candidate, BPL-003, is an intranasal formulation designed to address treatment-resistant depression. Phase 3 clinical trials are scheduled to commence later this quarter.
Compass Pathways, a United Kingdom-based biotechnology firm, is advancing COMP360, a synthetic psilocybin therapy. The compound is currently undergoing late-stage clinical evaluation for treatment-resistant depression and has received Breakthrough Therapy designation from the FDA.
The executive directive explicitly identifies ibogaine, a psychedelic compound extracted from an African plant species. Federal law currently categorizes it as a Schedule I controlled substance, indicating it is deemed to have no recognized medical application.
Researchers are investigating ibogaine as a potential intervention for opioid dependency. The directive mandates regulatory officials to facilitate access through the Right to Try Act, legislation Trump enacted in 2018.
Ibogaine has documented associations with cardiac complications, which has generated regulatory concerns.
Federal Investment and Industry Expert Commentary
President Trump announced that federal authorities will commit $50 million to support research efforts focused on ibogaine.
Jefferies analyst Andrew Tsai characterized the directive as an “official stamp of validation to the class,” emphasizing that governmental backing is now tangible.
RBC analyst Brian Abrahams stated the executive action “is a substantial step towards diminishing regulatory risk” for psychedelic medications.
Health Secretary Robert F. Kennedy Jr. has openly advocated for ibogaine as an alternative therapeutic approach for depression and related mental health disorders.
Bipartisan congressional representatives have indicated their intention to advance legislative measures that would broaden access to psychedelic treatment modalities.
FDA Commissioner Makary verified that the agency stands ready to act expeditiously under the new presidential directive.
